Biomarker News and Research RSS Feed - Biomarker News and Research

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Study suggests that variant of cell surface protein is ideal target to treat gastric cancer

New study by the Cancer Science Institute of Singapore and National University Hospital Singapore suggests that a variant of a cell surface protein is an ideal target for developing drugs to treat gastric cancer [More]
Researchers uncover novel function of Amyloid Precursor Protein linked to Alzheimer's disease

Researchers uncover novel function of Amyloid Precursor Protein linked to Alzheimer's disease

A research team led by the National Neuroscience Institute has uncovered a novel function of the Amyloid Precursor Protein (APP), one of the main pathogenic culprits of Alzheimer's disease. This discovery may help researchers understand how the protein goes awry in the brains of Alzheimer's disease patients, and potentially paves the way for the development of innovative therapeutics to improve the brain function of dementia patients. [More]
Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR). [More]

Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). [More]

Genoa Pharmaceuticals, McMaster University report additional benefits of GP-101 for IPF patients

Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, and collaborators Drs. Martin Kolb and Kjetil Ask at McMaster University announced today additional measured advantages of inhaled GP-101 (aerosol pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF). [More]
Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered a molecule, or biomarker, called CD61 on the surface of drug-resistant tumors that appears responsible for inducing tumor metastasis by enhancing the stem cell-like properties of cancer cells. [More]
Global cancer profiling market expected to grow $54.8 billion by 2018

Global cancer profiling market expected to grow $54.8 billion by 2018

Global Information Inc. announces the addition of a new market research report "Cancer Profiling and Pathways: Technologies and Global Markets" at GIIResearch.com. [More]
Protein expression predicts postop NSCLC recurrence, survival

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer. [More]
New study identifies potential target for colorectal cancer treatment

New study identifies potential target for colorectal cancer treatment

A new study identifies a molecule that is a probable driving force in colorectal cancer and suggests that the molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression. [More]
Researchers investigate role of microRNAs in breast cancer cells

Researchers investigate role of microRNAs in breast cancer cells

Metastasis — the spreading of cancer cells from a primary tumor site to other parts of the body — generally leads to poorer outcomes for patients, so oncologists and researchers are constantly seeking new ways to detect and thwart this malicious process. [More]

AES released list of new fellowship awardees for organization's early-career awards

Today, the American Epilepsy Society (AES) released its list of new fellowship awardees, naming 15 recipients for the organization's early-career awards. [More]
Lin28 gene may hold clues to regeneration of damaged kidneys in adults

Lin28 gene may hold clues to regeneration of damaged kidneys in adults

​Nearly one-third of cases of Wilms tumor, a pediatric cancer of the kidney, are linked to a gene called Lin28, according to research from Boston Children's Hospital. Mice engineered to express Lin28 in their kidneys developed Wilms tumor, which regressed when Lin28 was withdrawn, indicating that strategies aimed at blocking or deactivating the gene hold therapeutic promise for children with Wilms. [More]

Two candidate mTOR therapy biomarkers identified in RCC

Two genes, TSC1 and MTOR, warrant further investigation as biomarkers for treatment benefit with rapalogs in patients with renal cell carcinoma, indicate study results published in Clinical Cancer Research. [More]
miRNA expression and inhibition: an interview with Maja Petkovic, AMSBIO

miRNA expression and inhibition: an interview with Maja Petkovic, AMSBIO

RNA interference is a process in which RNA molecules inhibit gene expression. This gene silencing process is controlled by RNA-induced silencing complex or RISC and is initiated by small duplex RNA molecules or miRNA that is present inside cell plasma. [More]

Vibrational spectroscopy opens up new ways to diagnose chronic diseases

In today’s ageing population, resulting in a rising prevalence of chronic diseases such as neurodegeneration, the need for simple, non-invasive methods to diagnose or screen for important medical conditions becomes more and more relevant. Objective and cost-effective approaches capable of diagnosing early-stage disease in point-of-care clinical settings are necessary to facilitate the personalising of therapies to prevent or slow down pathology development. [More]
CAP receives CDC grants to improve adoption of evidence-based laboratory testing guidelines

CAP receives CDC grants to improve adoption of evidence-based laboratory testing guidelines

The College of American Pathologists (CAP), the world's largest organization of board-certified pathologists, has been awarded two grants from the Centers for Disease Control and Prevention (CDC). [More]
Stressful upbringings can leave imprints on genes of African American children

Stressful upbringings can leave imprints on genes of African American children

Stressful upbringings can leave imprints on the genes of children as young as age 9, according to a study led by Princeton University and Pennsylvania State University researchers. Such chronic stress during youth leads to physiological weathering similar to aging. [More]

bioTheranostics, Prime Health Services sign contract to expand genomic tests

bioTheranostics, Inc., the leading genomic solutions provider for cancer diagnosis, has signed a contract with Prime Health Services, Inc., a national preferred provider organization network, to cover the company's genomic tests for breast cancer patients and patients with metastatic disease. [More]

Nanostring Technologies launches nCounter PanCancer Pathways Panel

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced the launch of the nCounter® PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that offers a unique way for translational researchers to investigate cancer biology across all major cancer pathways. [More]
I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

I-SPY 2 trial qualifies neratinib for HER2-positive breast cancer

In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer. [More]